MARKET

GRAL

GRAL

Grail Inc
NASDAQ
13.82
-0.09
-0.65%
After Hours: 13.99 +0.17 +1.23% 17:31 11/06 EST
OPEN
13.65
PREV CLOSE
13.91
HIGH
14.21
LOW
13.52
VOLUME
483.16K
TURNOVER
--
52 WEEK HIGH
23.36
52 WEEK LOW
12.33
MARKET CAP
429.10M
P/E (TTM)
-0.2330
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GRAL last week (1028-1101)?
Weekly Report · 3d ago
Weekly Report: what happened at GRAL last week (1021-1025)?
Weekly Report · 10/28 12:32
GRAIL Presents Early Results From REFLECTION Real-World Evidence Study; Says Veteran Cohort Had Cancer Signal Detection Rate Consistent With Other Populations That Received MCED Test
Benzinga · 10/23 22:06
Grail presents initial results from study of Galleri multi-cancer detection test
TipRanks · 10/23 22:05
GRAIL PRESENTS INITIAL RESULTS FROM REFLECTION REAL-WORLD EVIDENCE STUDY OF GALLERI® MULTI-CANCER EARLY DETECTION (MCED) TEST AT THE EARLY DETECTION OF CANCER CONFERENCE
Reuters · 10/23 22:00
CEO & Director Of GRAIL Sold 51% Of Their Shares
Simply Wall St · 10/23 12:16
GRAIL APPOINTS SARAH KREVANS TO BOARD OF DIRECTORS
Reuters · 10/21 20:01
Press Release: GRAIL Appoints Sarah Krevans to Board of Directors
Dow Jones · 10/21 20:01
More
About GRAL
GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

Webull offers Grail Inc stock information, including NASDAQ: GRAL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRAL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRAL stock methods without spending real money on the virtual paper trading platform.